Back to News
Market Impact: 0.18
Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Inomagen Therapeutics received an award to fund key preclinical and manufacturing activities for its non-viral gene-therapy program. The funding is intended to advance the program toward a future Investigational New Drug application, representing a positive early-stage development milestone, though the award amount and program timeline were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Hong Kong Leader Unveils Five-Year Plan
- Why is Weichai Power stock rallying today?
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Trump calls Canada's potential EU associate membership 'laughable,' warns Europe of 'very heavy tariffs'
- AI Buildout Hits Inflation as Fed Hikes Rates
- US official says upcoming spectrum auctions could generate more than $100 billion
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers